Journal of Alzheimer's Disease
Published on Journal of Alzheimer's Disease (https://www.j-alz.com)

Home > Assessing the Progression of Alzheimer's Disease in Real-World Settings in Three European Countries.

TitleAssessing the Progression of Alzheimer's Disease in Real-World Settings in Three European Countries.
Publication TypeJournal Article
Year of Publication2021
AuthorsLladó, A, Froelich, L, Khandker, RK, Roset, M, Black, CM, Lara, N, Chekani, F, Ambegaonkar, BM
JournalJ Alzheimers Dis
Volume80
Issue2
Pagination749-759
Date Published2021
ISSN1875-8908
KeywordsAlzheimer Disease, Cholinesterase Inhibitors, Cognition Disorders, Disease Progression, Europe, Germany, Humans, Institutionalization, Neuropsychological Tests, Spain
Abstract

BACKGROUND: There exists considerable variation in disease progression rates among patients with Alzheimer's disease (AD).

OBJECTIVE: The primary objective of this observational study is to assess the progression of AD by characterizing cognitive, functional, and behavioral changes during the follow-up period between 6 and 24 months.

METHODS: A longitudinal prospective study with community-dwelling patients with an established clinical diagnosis of AD of mild to moderate severity was conducted in Germany, Spain and the UK. A sample of 616 patients from 69 sites was included.

RESULTS: Patients had a mean of 1.9 years (SD = 1.9) since AD diagnosis at study inclusion. Cognitive symptoms were reported to have first occurred a mean of 1.1 years (SD = 1.7) prior to AD diagnosis and 1.4 (SD = 1.8) years prior to AD treatment. Patients initially diagnosed with mild and moderate AD spent a median (95%CI) of 3.7 (2.8; 4.4) and 11.1 (6.1, 'not reached') years until progression to moderate and severe AD, respectively, according to the Mini-Mental State Examination (MMSE) scores. A mixed model developed for cognitive, functional, and neuropsychiatric scores, obtained from study patients at baseline and during follow-up period, showed progressive deterioration of AD patients over time.

CONCLUSION: The study showed a deterioration of cognitive, functional, and neuropsychiatric functions during the follow-up period. Cognitive deterioration was slightly faster in patients with moderate AD compared to mild AD. The duration of moderate AD can be overestimated due to the use of retrospective data, lack of availability of MMSE scores in clinical charts and exclusion of patients at time of institutionalization.

DOI10.3233/JAD-201172
Alternate JournalJ Alzheimers Dis
PubMed ID33579841
PubMed Central IDPMC8075403
E-mail Icon
Comment Icon
  • Comment
Bookmark Icon Bookmark Recommend Icon Recommend Follow Icon Follow
  • Comment
| Bookmark | Recommend | Follow

Source URL: https://www.j-alz.com/content/assessing-progression-alzheimers-disease-real-world-settings-three-european-countries